Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

<p>Abstract</p> <p>Background</p> <p>The aim of this study was to compare the responsiveness of the European Organization for Research and Treatment (EORTC) quality of life questionnaires (QLQ-C30, QLQ-CR38) and the Functional Assessment of Cancer Therapy-colorectal version 4 questionnaire (FACT-C).</p> <p>Method</p> <p>This prospective study included 127 patients with colorectal cancer: 71 undergoing chemotherapy and 56 radiation therapy. Responsiveness statistics included the Standardized Response Mean (SRM) and the Effect Size (ES). The patient's overall assessment of his/her change in state of health status was the reference criterion to evaluate the responsiveness of the QoL questionnaires.</p> <p>Results</p> <p>34 patients perceived their health as stable and 17 as improved between the first and the fourth courses of chemotherapy. 21 patients perceived their health as stable and 22 as improved between before and the last week of radiotherapy.</p> <p>The responsiveness of the 3 questionnaires differed according to treatments. The EORTC QLQ-C30 questionnaire was more responsive in patients receiving chemotherapy, particulary functional scales (SRM > 0.55). The QLQ-CR38 and the FACT-C questionnaires provided little clinically relevant information during chemotherapy or radiotherapy.</p> <p>Conclusion</p> <p>The EORTC QLQ-C30 questionnaire appears to be more responsive in patients receiving chemotherapy.</p

Radiothérapie des plasmocytomes solitaires extra médullaires de la tête et du cou (quelle dose prescrire)

Le but de notre travail était de ,détenniner la dose de radiothérapie à délivrer sur cible tumoral (CTV) pour les plasmocytomes solitaires. Matériels et Méthode: 17 patients (15 stade 1 et 2 stade Il) ont été traités pour plasmocytome solitaire extra médullaire de la tête et du cou au centre Alexis Vautrin 1979 et 2003. La dose moyenne prescrite sur le CTV était de 52,6 Gy (40-65 Gy) en fractions (20-30). Les patients stade II ont reçu une radiothérapie cervicale à 60 Gy. Cinq patients stade 1 ont reçu une irradiation prophylactique cervicale à la dose 36,4 Gy. La dose reçue au CTV a été évaluée sur les données dosimétriques 1 sur les clichés de centrage lorsqu'il n'y avait pas de dosimétrie. Deux groupes ont distingués: CTV couvert avec une dose ~ 40 Gy et CTV couvert avec une dose ~ 45 Gy. Résultats: le taux de contrôle local à 5 ans était de 72,8%. Il était de 100% quand la ,. reçue au CTV était ~ 45 Gy contre 50% lorsque la dose reçue au CTV était < 45 (p=0,034). Les facteurs pronostiques de la survie sans maladie (64,1 %) étaient la'- - monoclonale d'immunoglobuline (p=0,008) et une dose au CTV ~ 45 Gy (p=0,056). Conclusion: Une dose au CTV ~ 45 Gy semble améliorer le contrôle local. Une minimale de 45 Gy au CTV est recommandée.NANCY1-SCD Medecine (545472101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03).

International audienceBACKGROUND AND PURPOSE: The aim of this study was to prospectively assess the quality of life (QOL) of patients treated by concomitant chemo radiation for locally advanced anal canal carcinoma. MATERIALS AND METHODS: We report on a subgroup of 119 patients enrolled in a 306-patient therapeutic intensification prospective trial (ACCORD 03). This trial evaluated the impact on colostomy-free survival of induction chemotherapy and/or high dose radiotherapy (factorial design 2 *2 treatment arms). QOL was assessed both before and 2 months after treatment using the EORTC QLQ-C30 questionnaire as well as a questionnaire relating to anal sphincter conservative treatment (AS-CT). RESULTS: Compared to pre-treatment scores, patients reported significant improvement in their emotional function (+8.4 points p=0.002), global health status (+5.9 points p=0.0007), as well as a decrease in insomnia (-13.8 points p<0.0001), constipation (-12.0 points p<0.0001), appetite loss (-10.3 points p<0.0001) and pain (-9.6 points p=0.0002). The AS-CT degree of satisfaction with intestinal functions score was increased (+11.2 points p<0.0001). CONCLUSION: This is the first prospective study comparing QOL of patients with advanced anal canal carcinoma, before and 2 months after conservative treatment. Two months after treatment, QOL was improved. Induction chemotherapy and/or high dose radiotherapy did not provide a negative impact on QOL